Press Release

Capital increase met with good demand

Carl Zeiss Meditec AG raises proceeds of around €317m.¹

22 March 2017

Jena/Germany | Carl Zeiss Meditec AG

Carl Zeiss Meditec AG has successfully concluded a cash capital increase from authorized capital. Gross proceeds amount to approximately € 317 million.

The capital increase announced yesterday has been successfully completed. The order book was closed early due to the strong demand.

A total of 8,130,960 new shares were placed at a price of €38.94 per share. The Company plans to use the funds raised to drive forward its growth strategy.

Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG, gave his take on the successful conclusion of the capital increase: “We are delighted with the very strong demand for our new shares. These funds will provide us with the necessary power and flexibility to selectively exploit opportunities in our markets and to sustainably accelerate our growth. We would like to thank our new and existing shareholders for the high level of trust.”

Press & Investor Relations Contact Sebastian Frericks

Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220 116
investors.med@zeiss.com

Brief profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at www.zeiss.com/med

Further articles

12 September 2024

ZEISS Redefines Disease Management and Treatment within the ZEISS Retina Workflow

6 August 2024

Carl Zeiss Meditec closes first nine months of 2023/24 with slight decline in revenue

Press portal

Get all press releases of the Carl Zeiss Meditec AG here:

¹
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.